 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 April 1993 | Volume 118 Issue 7 | Pages 495-503
Objective: To evaluate the efficacy and safety of fluconazole for prevention of fungal infections.
Design: A randomized, placebo-controlled, double-blind, multicenter trial.
Patients: Adults (257) undergoing chemotherapy for acute leukemia.
Intervention: Patients were randomly assigned to receive either fluconazole (400 mg orally once daily or 200 mg intravenously every 12 hours) or placebo. The study drug was started at initiation of chemotherapy and continued until recovery of neutrophil count, development of proven or suspected invasive fungal infection, or the occurrence of a drug-related toxicity.
Measurements: Fungal colonization, proven superficial or invasive fungal infection, empiric antifungal therapy with amphotericin B, drug-related side effects, and mortality.
Main Results: Fluconazole decreased fungal colonization (83 of 122 [68%] placebo patients compared with 34 of 119 [29%] fluconazole patients colonized at end of prophylaxis, P < 0.001) and proven fungal infections (27 of 132 [21%] placebo patients compared with 11 of 123 [9%] fluconazole patients infected, P = 0.02). Superficial fungal infections occurred in 20 of 132 (15%) placebo patients but in only 7 of 123 (6%) fluconazole patients (P = 0.01), whereas invasive fungal infections developed in 10 of 132 (8%) placebo patients and in 5 of 123 (4%) fluconazole patients (P = 0.3). Fluconazole was especially effective in eliminating colonization and infection by Candida species other than Candida krusei (66 of 122 [64%] placebo patients colonized at end of prophylaxis compared with 11 of 119 (9%) fluconazole patients, P < 0.001; 22 of 132 (17%) placebo patients infected compared with 7 of 123 [6%] fluconazole patients, P = 0.005). Aspergillus infections were infrequent in both fluconazole (3 cases) and placebo groups (3 cases). The use of amphotericin B, the incidence of drug-related side effects, and overall mortality were similar in both study groups.
Conclusion: Prophylactic fluconazole prevents colonization and superficial infections by Candida species other than Candida krusei in patients undergoing chemotherapy for acute leukemia and is well tolerated. Fluconazole could not be clearly shown to be effective for preventing invasive fungal infections, reducing the use of amphotericin B, or decreasing the number of deaths.
Author and Article Information
For a list of investigators and institutions and
ARTICLE
Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial
Requests for Reprints: Drew J. Winston, MD, Room 42-121 CHS, Department of Medicine, UCLA Medical Center, Los Angeles, CA 90024.
Acknowledgments: The authors thank Patrick Robinson, MD, and Katharine Fry for preparation of the manuscript.
Grant Support: By grants CA-23175, CA-14548, and P30CA43703 from the National Cancer Institute and research grants from Pfizer Central Research, Groton, Connecticut.
This article has been cited by other articles:
|
|
 |
|
  E. Robenshtok, A. Gafter-Gvili, E. Goldberg, M. Weinberger, M. Yeshurun, L. Leibovici, and M. Paul Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis J. Clin. Oncol., December 1, 2007; 25(34): 5471 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Cornely, J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y.-T. Goh, et al. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia N. Engl. J. Med., January 25, 2007; 356(4): 348 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Charlier, E. Hart, A. Lefort, P. Ribaud, F. Dromer, D. W. Denning, and O. Lortholary Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother., March 1, 2006; 57(3): 384 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Lin, Y. Carmeli, J. Zumsteg, E. L. Flores, J. Tolentino, P. Sreeramoju, and S. G. Weber Prior Antimicrobial Therapy and Risk for Hospital-Acquired Candida glabrata and Candida krusei Fungemia: a Case-Case-Control Study Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4555 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Munoz, M. Sanchez-Somolinos, L. Alcala, M. Rodriguez-Creixems, T. Pelaez, and E. Bouza Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital J. Antimicrob. Chemother., February 1, 2005; 55(2): 188 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Waselenko, T. J. MacVittie, W. F. Blakely, N. Pesik, A. L. Wiley, W. E. Dickerson, H. Tsu, D. L. Confer, C. N. Coleman, T. Seed, et al. Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group Ann Intern Med, June 15, 2004; 140(12): 1037 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Cornely, A. J. Ullmann, and M. Karthaus Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies Blood, May 1, 2003; 101(9): 3365 - 3372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dainiak, J. K. Waselenko, J. O. Armitage, T. J. MacVittie, and A. M. Farese The Hematologist and Radiation Casualties Hematology, January 1, 2003; 2003(1): 473 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kaufman, R. Boyle, K. C. Hazen, J. T. Patrie, M. Robinson, and L. G. Donowitz Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants N. Engl. J. Med., December 6, 2001; 345(23): 1660 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Girmenia, L. Pagano, G. Leone, P. Martino, G. P. Bodey, H. A. Hanna, and I. I. Raad Fluconazole and Candida krusei Fungemia Arch Intern Med, October 8, 2001; 161(18): 2267 - 2269. [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Khan and J. R. Wingard Infection and Mucosal Injury in Cancer Treatment J Natl Cancer Inst Monographs, October 1, 2001; 2001(29): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laverdiere, C. Rotstein, E. J. Bow, R. S. Roberts, S. Ioannou, D. Carr, N. Moghaddam, and The Canadian Fluconazole Study Group Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients J. Antimicrob. Chemother., December 1, 2000; 46(6): 1001 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Abbas, G. P. Bodey, H. A. Hanna, M. Mardani, E. Girgawy, D. Abi-Said, E. Whimbey, R. Hachem, and I. Raad Candida krusei Fungemia: An Escalating Serious Infection in Immunocompromised Patients Arch Intern Med, September 25, 2000; 160(17): 2659 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Harousseau, A. W. Dekker, A. Stamatoullas-Bastard, A. Fassas, W. Linkesch, J. Gouveia, R. De Bock, M. Rovira, W. F. Seifert, H. Joosen, et al. Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B Antimicrob. Agents Chemother., July 1, 2000; 44(7): 1887 - 1893. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. W. Redding, R. C. Zellars, W. R. Kirkpatrick, R. K. McAtee, M. A. Caceres, A. W. Fothergill, J. L. Lopez-Ribot, C. W. Bailey, M. G. Rinaldi, and T. F. Patterson Epidemiology of Oropharyngeal Candida Colonization and Infection in Patients Receiving Radiation for Head and Neck Cancer J. Clin. Microbiol., December 1, 1999; 37(12): 3896 - 3900. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Winston, A. Pakrasi, and R. W. Busuttil Prophylactic Fluconazole in Liver Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, November 16, 1999; 131(10): 729 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Groll, V. Petraitis, R. Petraitiene, A. Field-Ridley, M. Calendario, J. Bacher, S. C. Piscitelli, and T. J. Walsh Safety and Efficacy of Multilamellar Liposomal Nystatin against Disseminated Candidiasis in Persistently Neutropenic Rabbits Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2463 - 2467. [Abstract] [Full Text]
|
|
|
|
|
|
C. Y. Turenne, S. E. Sanche, D. J. Hoban, J. A. Karlowsky, and A. M. Kabani Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System J. Clin. Microbiol., June 1, 1999; 37(6): 1846 - 1851. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. Boschman, U. R. Bodnar, M. A. Tornatore, A. A. Obias, G. A. Noskin, K. Englund, M. A. Postelnick, T. Suriano, and L. R. Peterson Thirteen-Year Evolution of Azole Resistance in Yeast Isolates and Prevalence of Resistant Strains Carried by Cancer Patients at a Large Medical Center Antimicrob. Agents Chemother., April 1, 1998; 42(4): 734 - 738. [Abstract] [Full Text]
|
|
|
|
|
|
R. Creger, K. Weeman, M. Jacobs, A Morrissey, P Parker, R. Fox, and H. Lazarus Lack of utility of the lysis-centrifugation blood culture method for detection of fungemia in immunocompromised cancer patients [In Process Citation] J. Clin. Microbiol., January 1, 1998; 36(1): 290 - 293. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Como and W. E. Dismukes Oral Azole Drugs as Systemic Antifungal Therapy N. Engl. J. Med., January 27, 1994; 330(4): 263 - 272. [Full Text]
|
|
Article
